CAR-T therapy study for rebuilding HIV immune defenses
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This early-stage study tests whether CAR-T cells can help rebuild the immune system’s ability to fight HIV. You may be a candidate if your HIV is well controlled on standard treatment and you don’t have certain serious infections or organ problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed HIV infection.
- You have been taking cART (standard HIV medicines) for more than 12 months.
- Your HIV viral load is very low (less than 50 copies/mL) and your CD4 count is above 350.
- You do not have serious problems with your heart, liver, or kidneys.
- You can understand the study, agree to participate, and sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell, called a CAR T cell, that is designed to target and kill cells infected with HIV. It may help control the virus without needing to take HIV medication all the time.
This trial tests whether CAR-T cells can help control HIV without daily antivirals. It is for people with well-controlled HIV who want to explore a potential functional cure.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.
This early-phase (Phase 1) study tests a lab-made immune cell treatment (CD4 CAR T) for people with CD4+ leukemia or lymphoma that has come back or did not respond to standard treatment. The goal is to check safety and see how well the treatment works.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
Hear when a new HIV/AIDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.